FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 489 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Registry Findings Highlight the Importance of Interdisciplinary Care in Rheumatic irAEs... September 21, 2020 Coronavirus and COVID-19: What People With Cancer Need to Know June 21, 2020 FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple... August 8, 2025 Born Blind With 50% Chance Of Survival, 20-Year-Old Musician Defied All... November 1, 2021 Load more HOT NEWS Adagrasib Demonstrates Clinical Activity Across a Broad Range of Tumour Types... Can Cooking With Nonstick Cookware Increase Your Cancer Risk? On Giving Tuesday, You Helped Us Raise $334,449 For People, Pets,... Toddler Hailed A Hero After He Saved His Family From Fire...
